Rhizen Pharmaceuticals S.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
7
Ending by 2030
Oct 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Substituted chromenones as modulators of protein kinases (US 10,322,130) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (US 10,414,773) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Novel Selective PI3K Delta Inhibitors (US 9,150,579) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Novel Kinase Modulators (US 11,858,907) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Novel Selective PI3K Delta Inhibitors (US 10,570,142) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,921,364 | Modulators of calcium release-activated calcium channel In force · From the USPTO record | In force | From the USPTO record | |
| US 9,758,514 | Modulators of calcium release-activated calcium channel In force · From the USPTO record | In force | From the USPTO record | |
| US 10,246,450 | Modulators of calcium release-activated calcium channel In force · From the USPTO record | In force | From the USPTO record | |
| US 8,642,607 | 4H-CHROMEN-4-ONE Compounds as Modulators of Protein Kinases In force · High confidence | In force | High confidence | |
| US 9,018,375 | Substituted Chromenes as Kinase Modulators In force · Medium confidence | In force | Medium confidence | |
| US 11,858,907 | Novel Kinase Modulators In force · Low confidence | In force | Low confidence | |
| US 8,377,970 | Modulators of calcium release-activated calcium channel In force · From the USPTO record | In force | From the USPTO record | |
| US 9,758,474 | Immunomodulator and anti-inflammatory compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,686,048 | Immunomodulator and anti-inflammatory compounds In force · From the USPTO record | In force | From the USPTO record | |
| US 10,220,035 | Novel Compounds as Modulators of Protein Kinases In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 21: 37 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 6 abandoned · 16 no status recorded